Business Wire

bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...
Business Wire

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy

CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...